Boundless Bio, Inc.(BOLD) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track for mid-2025 development candidate nomination and IND filing in the first half of 2026 $138 million cash position provides operating runway into 2027 BBI-355, a novel, oral, potent CHK1 inhibitor designed to target repli ...